Abstract |
Intravenous-bolus etoposide has modest activity in sarcomas when given daily for 3-5 days. Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. A phase I trial of oral etoposide resulted in partial responses in two patients with soft-tissue sarcomas. To estimate more accurately the response rate for daily oral etoposide in sarcomas, we treated 25 patients with 50 mg/m2 per day by mouth for 21 days every 4 weeks. Treatment-related toxicity included > or = grade 2 neutropenia in 6 of the 25 patients and thrombocytopenia in 3. One brief partial response was observed (4%; 95% confidence interval for true response rate, 0-11%). Disease stabilized in five patients for periods ranging from 3 to 18 months. At this dose and on this schedule, daily oral etoposide appears to have little activity against soft-tissue sarcomas.
|
Authors | J D Licht, R Mazanet, P J Loehrer, R Gonin, K H Antman |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 34
Issue 1
Pg. 79-80
( 1994)
ISSN: 0344-5704 [Print] Germany |
PMID | 8174207
(Publication Type: Clinical Trial, Clinical Trial, Phase IV, Journal Article)
|
Chemical References |
|
Topics |
- Administration, Oral
- Adult
- Aged
- Drug Administration Schedule
- Etoposide
(administration & dosage, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Sarcoma
(drug therapy, secondary)
|